Valdoxan - a melatonergic antidepressant - receives positive European opinion for major depressive disorder
Today, the average size soft drink is 20 ounces and contains 17 teaspoons of sugar. More startling is that some citric acids found in fruit drinks are more erosive than hydrochloric or sulfuric acid - which is also known as battery acid. These refined sugars and acids found in soda and citrus juice promote tooth
Full Post: Drink tea instead of soft drinks to avoid tooth erosion
The first melatonergic antidepressant - Valdoxan/Thymanax (agomelatine) - has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD).
Upon approval by the European Commission in early 2009, Valdoxan is expected to be marketed by Servier in European countries in the following months.
Valdoxan is an innovative, new approach to the treatment of MDD, and has proven efficacy across a wide range of patients, including the most severely depressed. The new drug, Valdoxan, compares favourably with the most currently-prescribed antidepressants and offers new hope to the 33 million people in Europe who suffer from MDD, a disease for which there is still a significant medical need for improved management of patients’ depressive symptoms.
Evidence of Valdoxan’s antidepressant efficacy
Data from its clinical development programme show that Valdoxan is effective against the core symptoms of depression, including depressed mood, anxiety, psychomotor retardation, sleep disturbances, and daytime fatigue, leading depressed patients to a more complete and sustained remission.
Valdoxan has proven efficacy in moderately and severely adult depressed patients (18-65 years old) presenting a first or recurrent episode of MDD. Valdoxan has been demonstrated to be effective at every step of depression treatment, with significant early improvement reported by both clinicians and patients as soon as the first week of treatment.
The antidepressant efficacy has been shown at a once-daily dose of 25 mg in most patients. Both short-term and long-term results from the large, comprehensive, international development programme including nearly 4000 adult patients with MDD were presented to the CHMP to support the efficacy of Valdoxan as compared with placebo, selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitor (SNRI) treatments. This programme also showed that Valdoxan’s antidepressant efficacy was combined with a favourable tolerability profile compared with other treatments, resulting in better adherence and remission in depressed patients.
Valdoxan: a novel and promising approach to treating depression
Valdoxan, the result of an advanced pharmacological research programme involving investigation centres all around the world, is the first melatonergic antidepressant. As a MT1 and MT2 receptor agonist and a 5-HT2C receptor antagonist, Valdoxan acts by resynchronizing circadian rhythms. Its mechanism of action is unlike those of the commonly-prescribed antidepressants the SSRIs and SNRIs, since Valdoxan exerts its antidepressant efficacy without impacting on serotonin levels.
Valdoxan/Thymanax was discovered and developed by Servier, France’s leading independent pharmaceutical company.
A new study shows that antidepressant drugs which only affect serotonin, often used as first choice treatments, may not be best for depression in people with Parkinson’s disease. The new research is published in the December 17, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology. Depression affects up to
Full Post: Tricyclic antidepressants best for depression in Parkinson’s
The use of antidepressant medications by patients with fibromyalgia syndrome is associated with a reduction in pain, sleep disturbances and depressed mood and improvement of health-related quality of life, according to an analysis of previous studies, which is published in the January 14 issue of JAMA. Fibromyalgia syndrome (FMS), which consists of chronic widespread pain
Full Post: Antidepressants improve symptoms of fibromyalgia
Scientists at the University of Liverpool have developed a therapy programme to treat depression in women in developing countries. Although depression is a major health problem world-wide, experts say its impact is greatest in developing countries where 80% of the population live. Often there are no resources available to treat sufferers. Professor Atif Rahman from
Full Post: Scientists create therapy programme to treat depression in women in developing countries
Scientists at the University of Liverpool have developed a therapy programme to treat depression in women in developing countries. Although depression is a major health problem world-wide, experts say its impact is greatest in developing countries where 80% of the population live. Often there are no resources available to treat sufferers. Professor Atif Rahman
Full Post: Study improves recovery for mothers with depression
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company’s novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA). The action date under the Prescription Drug User
Full Post: FDA accepts Labopharm’s NDA for formulation of trazodone